IBI38D9-L
IBI38D9-L is a human IgG1-type CD79b/CD3 bispecific T-cell engager. IBI38D9-L binds to human CD79b and CD3 with Kd values of 1.45 nM and 119 nM, respectively. IBI38D9-L mediates tumor cell recognition and T-cell engagement, activating T cells and inducing their proliferation and release of cytotoxic molecules. IBI38D9-L exerts T cell-mediated cytotoxicity in a tumor cell-dependent manner, thereby selectively depleting antigen-positive malignant B cells. IBI38D9-L can be used for research on B-cell non-Hodgkin lymphoma.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
Species Reactivity
Human
IC50 & Target
[1]|
CD79b 1.45 nM (Kd) |
CD3 119 nM (Kd) |
体外実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOG (female, reconstituted with human PBMCs)[1]
-
Dosage:1 mg/kg
-
Administration:on days 8, 12, 15, 19, and 22
-
Result:Produced a tumor growth inhibition (TGI) of 73% at 1 mg/kg.
No body weight reduction or overt toxicities were observed.
-
Animal Model:NOG (female, reconstituted with human PBMCs)[1]
-
Dosage:3 mg/kg
-
Administration:on days 6, 9, 13, 16, and 20
-
Result:Produced a tumor growth inhibition (TGI) of 62% at 3 mg/kg.
No body weight reduction or overt toxicities were observed.
-
Animal Model:NOG (female, reconstituted with human PBMCs)[1]
-
Dosage:3 mg/kg
-
Administration:once
-
Result:Compared with control, IBI38D9-L increased tumor-infiltrating CD4+ and CD8+ T cells on both days 1 and 3 after administration.
Activated T cells (CD4+CD25+ or CD8+CD25+) were increased in tumor samples from the treated group.
Intracellular granzyme B and perforin within CD4+ and CD8+ T cells showed similar trends to CD25.
Immunofluorescence confirmed elevated CD3+ T cell infiltration in tumors from treated animals.
-
Animal Model:HSC-NPG (female, engrafted with human CD34+ hematopoietic stem cells)[1]
-
Dosage:3 mg/kg and 10 mg/kg
-
Administration:on days 0, 7, 14, and 21
-
Result:Produced a large decrease in B cells in peripheral blood at day 3 after the first dose at 3 and 10 mg/kg, with almost no B cells detected on day 10 and thereafter.
No loss of CD3+ T cells was observed at day 3; however, almost no CD3+ T cells were detected at day 10 onwards.
Target
CD79b & CD3
Conjugated
Unconjugated
アプリケーション
ELISA, FACS, Functional assay
化学情報
-
SMILES
[IBI38D9-L]
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
IBI38D9-L 関連分類
HY-P992547 関連分類
Powered by Bioz